Overview |
bs-5714R |
OVCA1 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human |
Mouse, Rat, Dog, Cow, Horse, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human OVCA1 |
251-350/443 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
1801 |
Candidate tumor suppressor in ovarian cancer 1; Diphthamide biosynthesis protein 1; Diphthamide biosynthesis protein 2 homolog like 1; Diphthamide biosynthesis protein 2 like; Diptheria toxin resistance protein required for diphthamide biosynthesis Saccharomyces like 1 ; Diptheria toxin resistance protein required for diphthamide biosynthesis like 1; DPH like 1 S. cerevisiae; DPH like 1; DPH1; DPH1 homolog S. cerevisiae; DPH1 homolog; DPH2 like 1; DPH2L; DPH2L1; HsDph1; Ovarian cancer associated gene 1; Ovarian cancer associated gene 1 protein; Ovarian tumor suppressor candidate 1; DPH1_HUMAN. |
OVCA1 is required for the first step in the synthesis of diphthamide, a unique posttranslationally modified histidine found only in translation elongation factor-2 (EEF2; MIM 130610). This modification is conserved from archaebacteria to humans and serves as the target for ADP-ribosylation and inactivation of EEF2 by diphtheria toxin (DT) and Pseudomonas exotoxin A. OVCA1 is one of several enzymes involved in synthesis of diphthamide in EEF2. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |